Skip to main content
Equibles

LMR Partners LLP

Position in SMMT — Summit Therapeutics Inc.

CIK 1578621 LONDON, X0
Back to SMMT Full portfolio

Position in SMMT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,401,298
+$754,346 QoQ
Shares Held
96,177
+181.9% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#78
of 242 holders
Holding Since
Mar 2021
11 quarters on record
Voting authority Sole 70% Shared 30% None 0%

Common Shares in SMMT Over Time

Shares Held

Position Value (USD)

Derivatives in SMMT

reported options exposure · as of Jun 30, 2026
CallValue
$1,458,457
CallShares
100,100
PutValue
$11,953,228
PutShares
820,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

LMR Partners LLP holds $188,560,243 across 74 Biotechnology names. SMMT ranks #28 (0.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 134,214 $40,402,439
2 DNTH
Dianthus Therapeutics, Inc. /DE/
 223,995 $21,835,032
3 REGN
Regeneron Pharmaceuticals, Inc.
 22,306 $13,908,683
4 TNGX
Tango Therapeutics, Inc.
 347,106 $10,850,533
5 RVMD
Revolution Medicines, Inc.
 5,112,098 $8,521,240
6 ARGX
Argenx SE
 8,200 $7,607,714
7 DFTX
Definium Therapeutics, Inc.
 150,200 $7,065,408
8 NKTR
Nektar Therapeutics
 100,000 $6,981,000

All Filings in SMMT

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,401,298 96,177
2026-06-30 $1,458,457 100,100
2026-06-30 $11,953,228 820,400
2026-03-31 $11,383,584 600,400
2026-03-31 $949,896 50,100
2026-03-31 $646,952 34,122
2025-12-31 $7,422,756 424,400
2025-12-31 $1,315,248 75,200
2025-09-30 $8,452,006 409,100
2025-06-30 $3,911,264 183,800
2025-03-31 $2,638,872 136,800
2024-12-31 $2,173,521 121,800
2024-09-30 $2,190,000 100,000
2024-06-30 $390,000 50,000
2023-03-31 $112,588 64,336
2021-03-31 $84,275 14,357